An2 Therapeutics Stock Performance
| ANTX Stock | USD 1.07 0.01 0.93% |
The firm owns a Beta (Systematic Risk) of 0.6, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, AN2 Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding AN2 Therapeutics is expected to be smaller as well. At this point, AN2 Therapeutics has a negative expected return of -0.17%. Please make sure to confirm AN2 Therapeutics' information ratio, as well as the relationship between the kurtosis and period momentum indicator , to decide if AN2 Therapeutics performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days AN2 Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
1 | Acquisition by Fitzpatrick Margaret M of 8610 shares of AN2 Therapeutics at 1.1769 subject to Rule 16b-3 | 05/28/2025 |
2 | James River Church Releases Worship Anthem and New Single Defender | 05/29/2025 |
3 | Elie Kamanos Anthem Amplifies Pan-African Reparations Call with Striking New Music Video | 06/12/2025 |
4 | Cage The Elephant announces 2025 tour, two NY shows. Get tickets | 06/25/2025 |
5 | C.M. James Drops 3 Shots The Drink-A-Long Song of the Summer, Debuts with Buzz, Challenge, and Barroom Anthem Energy | 07/07/2025 |
6 | If you lived or worked in Northern California and paid any portion of premiums for health insurance from Aetna, Anthem Blue Cross, Blue Shield of California, He... | 07/08/2025 |
7 | Katseye announces Beautiful Chaos Tour, NYC show. Get tickets today | 07/10/2025 |
8 | Pollock Cohen and Walden Macht File Class Action Against Anthem Health Plans, Carelon and Parent-Company Elevance | 07/15/2025 |
9 | Today, I.M.P. Stands for Its My Potato as The Anthem Unveils New European-Style French Fry Stand on The Wharf, FRITES AND GREET | 07/16/2025 |
10 | Explore Anthem Country Club Homes For Sale in Las Vegas From Las Vegas Homes By Leslie - REMAX United Realtor | 07/18/2025 |
11 | AN2 Therapeutics Inc. Stock Analysis and Forecast - Consistent double returns - jammulinksnews.com | 07/22/2025 |
12 | ANTX AN2 Therapeutics Partners on Chagas Disease Oral Treatment ANTX Stock News | 07/23/2025 |
13 | National University Releases The Whole You, an Anthem to Celebrate ANDers and the Changing Face of Higher Education | 07/28/2025 |
| Begin Period Cash Flow | 15.6 M | |
| Total Cashflows From Investing Activities | 54.6 M |
AN2 Therapeutics Relative Risk vs. Return Landscape
If you would invest 122.00 in AN2 Therapeutics on May 2, 2025 and sell it today you would lose (15.00) from holding AN2 Therapeutics or give up 12.3% of portfolio value over 90 days. AN2 Therapeutics is currently does not generate positive expected returns and assumes 3.1198% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than AN2, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AN2 Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AN2 Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AN2 Therapeutics, and traders can use it to determine the average amount a AN2 Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0533
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ANTX |
Estimated Market Risk
| 3.12 actual daily | 27 73% of assets are more volatile |
Expected Return
| -0.17 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average AN2 Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AN2 Therapeutics by adding AN2 Therapeutics to a well-diversified portfolio.
AN2 Therapeutics Fundamentals Growth
AN2 Stock prices reflect investors' perceptions of the future prospects and financial health of AN2 Therapeutics, and AN2 Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AN2 Stock performance.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (62.96 M) | ||||
| Shares Outstanding | 30.18 M | ||||
| Price To Earning | 3.96 X | ||||
| Price To Book | 0.44 X | ||||
| EBITDA | (51.32 M) | ||||
| Net Income | (51.32 M) | ||||
| Cash And Equivalents | 113.39 M | ||||
| Cash Per Share | 5.84 X | ||||
| Total Debt | 10.24 M | ||||
| Current Ratio | 28.17 X | ||||
| Book Value Per Share | 2.43 X | ||||
| Cash Flow From Operations | (49.26 M) | ||||
| Earnings Per Share | (1.51) X | ||||
| Market Capitalization | 32.59 M | ||||
| Total Asset | 92.09 M | ||||
| Retained Earnings | (205.78 M) | ||||
| Working Capital | 76.02 M | ||||
About AN2 Therapeutics Performance
Evaluating AN2 Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if AN2 Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AN2 Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.56) | (0.59) | |
| Return On Capital Employed | (0.67) | (0.70) | |
| Return On Assets | (0.56) | (0.59) | |
| Return On Equity | (0.63) | (0.60) |
Things to note about AN2 Therapeutics performance evaluation
Checking the ongoing alerts about AN2 Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AN2 Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AN2 Therapeutics generated a negative expected return over the last 90 days | |
| AN2 Therapeutics has some characteristics of a very speculative penny stock | |
| AN2 Therapeutics has high historical volatility and very poor performance | |
| AN2 Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (51.32 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| AN2 Therapeutics currently holds about 113.39 M in cash with (49.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| AN2 Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 23.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: National University Releases The Whole You, an Anthem to Celebrate ANDers and the Changing Face of Higher Education |
- Analyzing AN2 Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AN2 Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining AN2 Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AN2 Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of AN2 Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AN2 Therapeutics' stock. These opinions can provide insight into AN2 Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.